LU83962A1 - Nouveau compose utile comme medicament antitussif et son procede de preparation - Google Patents
Nouveau compose utile comme medicament antitussif et son procede de preparation Download PDFInfo
- Publication number
- LU83962A1 LU83962A1 LU83962A LU83962A LU83962A1 LU 83962 A1 LU83962 A1 LU 83962A1 LU 83962 A LU83962 A LU 83962A LU 83962 A LU83962 A LU 83962A LU 83962 A1 LU83962 A1 LU 83962A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- compound
- preparation
- antitussitive
- compound useful
- novel compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title description 5
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 4-phenyl-1-piperazinio-1-yl Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 229940124584 antitussives Drugs 0.000 claims description 3
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000000954 anitussive effect Effects 0.000 description 5
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 4
- QPEDEFUKFNFHMX-UHFFFAOYSA-O 1-(4-phenylpiperazin-1-ium-1-ylidene)propane-1,2-diol Chemical compound C1C[N+](=C(O)C(O)C)CCN1C1=CC=CC=C1 QPEDEFUKFNFHMX-UHFFFAOYSA-O 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- YULDSZDAYLSADA-UHFFFAOYSA-N 1-(4-phenylpiperazin-1-yl)propane-1,2-diol Chemical compound C1CN(C(O)C(O)C)CCN1C1=CC=CC=C1 YULDSZDAYLSADA-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LAOROLNDGSJOEB-UHFFFAOYSA-N 3-(2-chlorophenothiazin-10-yl)-n,n-dimethylpropan-1-amine;4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one;n-(4-ethoxyphenyl)acetamide;1,3,7-trimethylpurine-2,6-dione Chemical compound CCOC1=CC=C(NC(C)=O)C=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1.C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 LAOROLNDGSJOEB-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000000294 tussive effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT934381 | 1981-02-25 | ||
| IT8109343A IT1210639B (it) | 1981-02-25 | 1981-02-25 | Prodotto: 3(4-fenil1piperazinio-1-il)-1,2-propandiolo 3(teofillin-7-il)-1propansolfonato,utilizzabile in terapia,e relativo procedimento di fabbricazione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU83962A1 true LU83962A1 (fr) | 1982-07-08 |
Family
ID=11128724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU83962A LU83962A1 (fr) | 1981-02-25 | 1982-02-23 | Nouveau compose utile comme medicament antitussif et son procede de preparation |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4372958A (en, 2012) |
| JP (1) | JPS57188589A (en, 2012) |
| AT (1) | AT380881B (en, 2012) |
| BE (1) | BE892271A (en, 2012) |
| CA (1) | CA1192549A (en, 2012) |
| CH (1) | CH651043A5 (en, 2012) |
| DE (1) | DE3205149A1 (en, 2012) |
| DK (1) | DK148687C (en, 2012) |
| ES (1) | ES8302680A1 (en, 2012) |
| FR (1) | FR2500455A1 (en, 2012) |
| GB (1) | GB2093445B (en, 2012) |
| GR (1) | GR76060B (en, 2012) |
| IT (1) | IT1210639B (en, 2012) |
| LU (1) | LU83962A1 (en, 2012) |
| NL (1) | NL8200746A (en, 2012) |
| PT (1) | PT74463B (en, 2012) |
| SE (1) | SE440503B (en, 2012) |
| YU (1) | YU44007B (en, 2012) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1203721B (it) * | 1983-12-29 | 1989-02-23 | Dompe Farmaceutici Spa | Composti otticamente attivi ad attivita' antitosse e sedativa centrale,procedimento per la preparazione e composizioni che li contengono |
| IT1217950B (it) * | 1988-06-28 | 1990-03-30 | Dott Formenti Ind Chimica E Fa | Sali di (r,s) 3 (4 fenil 1 piperazinil) 1,2 propandtolo |
| IT1231158B (it) * | 1989-07-20 | 1991-11-19 | Dompe Farmaceutici Spa | Procedimento per la risoluzione ottica della dropropizina. |
| DE3938123A1 (de) * | 1989-11-16 | 1991-05-23 | Diehl Gmbh & Co | Treibladungsanzuender |
| IT1318651B1 (it) * | 2000-07-28 | 2003-08-27 | Dompe Spa | Sintesi di (+-)1,3-diossolani e loro risoluzione ottica. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3163649A (en) * | 1964-12-29 | Substituteb phenyl-piperazine | ||
| GB938646A (en) * | 1961-03-16 | 1963-10-02 | Henri Morren | New piperazine derivatives |
| FR1384693A (fr) * | 1963-10-08 | 1965-01-08 | Electrochimie Soc | Procédé de préparation d'esters méthallyliques |
| FR1554628A (en, 2012) * | 1967-05-23 | 1969-01-24 |
-
1981
- 1981-02-25 IT IT8109343A patent/IT1210639B/it active
- 1981-05-22 GB GB8115803A patent/GB2093445B/en not_active Expired
- 1981-06-10 US US06/272,281 patent/US4372958A/en not_active Expired - Fee Related
-
1982
- 1982-02-13 DE DE19823205149 patent/DE3205149A1/de active Granted
- 1982-02-17 AT AT0059982A patent/AT380881B/de not_active IP Right Cessation
- 1982-02-19 PT PT74463A patent/PT74463B/pt unknown
- 1982-02-23 LU LU83962A patent/LU83962A1/fr unknown
- 1982-02-23 GR GR67396A patent/GR76060B/el unknown
- 1982-02-24 YU YU412/82A patent/YU44007B/xx unknown
- 1982-02-24 JP JP57027570A patent/JPS57188589A/ja active Granted
- 1982-02-24 ES ES509850A patent/ES8302680A1/es not_active Expired
- 1982-02-24 CA CA000397008A patent/CA1192549A/en not_active Expired
- 1982-02-24 DK DK79982A patent/DK148687C/da active
- 1982-02-24 NL NL8200746A patent/NL8200746A/nl not_active Application Discontinuation
- 1982-02-25 CH CH1167/82A patent/CH651043A5/it not_active IP Right Cessation
- 1982-02-25 FR FR8203164A patent/FR2500455A1/fr active Granted
- 1982-02-25 SE SE8201184A patent/SE440503B/sv not_active IP Right Cessation
- 1982-02-25 BE BE0/207403A patent/BE892271A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3205149A1 (de) | 1982-11-11 |
| SE440503B (sv) | 1985-08-05 |
| FR2500455A1 (fr) | 1982-08-27 |
| AT380881B (de) | 1986-07-25 |
| BE892271A (fr) | 1982-06-16 |
| YU44007B (en) | 1990-02-28 |
| GB2093445B (en) | 1985-02-27 |
| DK148687C (da) | 1986-04-28 |
| PT74463B (en) | 1983-08-24 |
| CA1192549A (en) | 1985-08-27 |
| IT1210639B (it) | 1989-09-14 |
| FR2500455B1 (en, 2012) | 1984-04-27 |
| SE8201184L (sv) | 1982-08-26 |
| PT74463A (en) | 1982-03-01 |
| DE3205149C2 (en, 2012) | 1991-04-18 |
| ES509850A0 (es) | 1983-02-01 |
| JPS57188589A (en) | 1982-11-19 |
| CH651043A5 (it) | 1985-08-30 |
| IT8109343A0 (it) | 1981-02-25 |
| JPH0333715B2 (en, 2012) | 1991-05-20 |
| GB2093445A (en) | 1982-09-02 |
| ATA59982A (de) | 1985-12-15 |
| US4372958A (en) | 1983-02-08 |
| DK79982A (da) | 1982-08-26 |
| NL8200746A (nl) | 1982-09-16 |
| ES8302680A1 (es) | 1983-02-01 |
| DK148687B (da) | 1985-09-02 |
| YU41282A (en) | 1987-10-31 |
| GR76060B (en, 2012) | 1984-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4072759A (en) | Novel benzylalcohol derivatives as antidiabetics and cardiotonics | |
| EP0154756B1 (fr) | Citrate de vinpocetine et son procédé de préparation | |
| BG65924B1 (bg) | Хидрохлоридни соли на 5 - [4-[2-(n-метил-n-[2-пиридил]амино] етокси] бензил] тиазолидин - 2, 4 - дион | |
| HU206110B (en) | Process for producing azelatine salts with improved solubility and pharmaceutical compositions comprising same | |
| JPS62212322A (ja) | 医薬組成物および処置法 | |
| HU209308B (en) | Process for producing codeine salt of substituted carboxylic acid | |
| LU83962A1 (fr) | Nouveau compose utile comme medicament antitussif et son procede de preparation | |
| JPH072831A (ja) | ベータ−３選択性アドレナリン作動剤としてのアミノシクロアルカノベンゾジオキソール類 | |
| EP0038343A1 (de) | Substituierte oxocarbonsäuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel. | |
| EP0001021A2 (fr) | Nouveaux dérivés d'alcaloides pentacycliques, procédé de préparation, application à la synthèse de produits du groupe de l'éburnamonine et compositions pharmaceutiques | |
| JPS59144763A (ja) | １−〔１−ベンズイミダゾリル〕−ｎ−〔２−（４−ヒドロキシ−３−メトキシフエニル）−２−ヒドロキシエチル〕−３−アミノブタン化合物、該化合物を含有する医薬、及び該化合物の製 | |
| FR2499981A1 (fr) | Acides amino-2 halogenobenzoyl-3 methylphenylacetiques et leurs esters et sels utiles comme medicaments anti-inflammatoires et analgesiques | |
| UA52661C2 (uk) | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти | |
| FR2827284A1 (fr) | Nouveaux derives de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| CH641775A5 (fr) | N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment. | |
| FR2527605A1 (fr) | Derives de piperazine, procede de fabrication et medicaments en resultant | |
| CA2442468A1 (en) | Therapeutic agent for bladder hypersensitivity | |
| FR2468598A1 (fr) | Thiazolidones-4 substituees en 2, leur procede de preparation et les medicaments les contenant | |
| DE3812755A1 (de) | Salicylsaeurederivate | |
| US4349547A (en) | Suppressing obesity and over-secretion of insulin with 2-(α-hydroxy-m-trifluoromethylbenzyl)azetidine | |
| JPH0772190B2 (ja) | ヒダントイン誘導体 | |
| US5039679A (en) | Certain derivatives of 1,4-dihydro-5-isopropoxy-1,6-naphthyridine-3-carboxylic acid, pharmaceutical compositions containing them, and methods of using them | |
| JPS58219160A (ja) | 特に心臓血管系において活性であるトリプタミンの新しい誘導体、およびこの物質の合成方法、およびこの物質を含む薬品 | |
| US7763625B2 (en) | Agents for treating migraine | |
| US3737540A (en) | Composition for suppressing the tremor of parkinson's syndrome |